ARTICLE | Company News
Xytis Pharmaceuticals, Fournier deal
June 20, 2005 7:00 AM UTC
Fournier granted Xytis an exclusive worldwide license to Anatibant (LF-16-0687MF) to treat traumatic brain injury. The non-peptide bradykinin B2 antagonist has completed Phase I testing and has Orphan...